How to Fight Insurance Denials for Compounded GLP-1 Medications

Compounded semaglutide and tirzepatide became the unexpected backbone of obesity treatment in America during the FDA drug shortage from 2022 through early 2025. Millions of patients accessed these medications through telehealth platforms like Hims, Henry Meds, Mochi, Eden, Ro, and Future, paying $200-$500 per month out of pocket while branded Wegovy and Zepbound were unavailable or unaffordable. When the FDA removed semaglutide from the shortage list in February 2025 and tirzepatide in December 2024, the legal landscape shifted overnight. Insurers now routinely deny coverage for compounded GLP-1s as "not FDA-approved," "investigational," or "cosmetic." Patients seeking retroactive reimbursement for thousands of dollars in cash payments are told their claims are impossible. Self-funded employer plans cite blanket exclusions for weight-loss medications. But federal law—specifically 21 USC §353a and §353b governing compounding pharmacies, plus ACA external review rights—creates multiple avenues for appeal. This guide walks through the most common denial templates and how to counter them with the specific legal citations, clinical evidence, and procedural rights that insurers must respect.

Why Insurers Deny Compounded GLP-1 Coverage

Insurance companies use a predictable set of templates to deny compounded semaglutide and tirzepatide claims. Understanding these patterns is the first step in building a successful appeal.

1. "Not FDA-approved" or "Investigational"

This is the most common reflexive denial. The insurer states that compounded medications are not FDA-approved products and therefore fall outside covered benefits. The denial may cite a policy requiring "FDA-approved medications only" or label compounded drugs as "investigational" or "experimental."

2. "Weight-loss medication exclusion"

Many employer-sponsored plans—particularly self-funded ERISA plans—include explicit carve-outs for anti-obesity medications (AOMs). These exclusions typically state that "medications prescribed for weight loss are not covered, including but not limited to phentermine, orlistat, naltrexone-bupropion, semaglutide, tirzepatide," regardless of whether the drug is branded or compounded.

3. "No retroactive reimbursement for out-of-network cash purchases"

For patients seeking reimbursement of past cash payments made during the shortage period, insurers often claim that because the patient did not obtain prior authorization, paid a non-network pharmacy directly, or received care from a telehealth provider not in the network, the claims are categorically ineligible for reimbursement.

4. "Shortage ended—compounding no longer permitted"

Post-February 2025 for semaglutide and post-December 2024 for tirzepatide, insurers deny continued compounded prescriptions by citing the FDA's removal of these drugs from the shortage list. The insurer argues that under 21 USC §353a, compounding is only permitted during a shortage, and now that branded products are available, compounding is illegal or at minimum not a covered benefit.

5. "Compounded combination products are not medically necessary"

Patients who transitioned to compounded semaglutide + B12 or tirzepatide + B12/niacinamide combinations (a common workaround post-shortage) face denials stating these are "not medically necessary," "not evidence-based," or that the addition of B12 or other ingredients is "not clinically justified." Insurers may call these "essentially copies" of the branded drug designed to circumvent shortage restrictions.

The Citations Insurers Respect

Successful compounded GLP-1 appeals rely on specific legal authorities, clinical trials, and regulatory guidance that insurers cannot easily dismiss. Use these by name and year in your appeal letters.

21 USC §353a (Federal Food, Drug, and Cosmetic Act Section 503A)

This federal statute governs traditional compounding pharmacies (503A). It permits compounding of drugs that are in shortage or when a prescriber determines a commercially available product cannot meet a patient's medical needs. Critically, it allows compounding for individual patient prescriptions and does not require FDA approval of the compounded product. When an insurer claims compounded drugs are "not FDA-approved," §353a is your first line of defense: the statute explicitly authorizes compounding outside the FDA approval pathway for individualized patient care.

21 USC §353b (Section 503B—Outsourcing Facilities)

This statute governs outsourcing facilities, which operate under current Good Manufacturing Practice (cGMP) standards and can produce larger batches of compounded drugs. 503B facilities are a distinct regulatory tier from 503A and may compound drugs not on the shortage list if they meet patient-specific needs. If your compounded GLP-1 came from a 503B facility, cite this statute to demonstrate higher manufacturing standards and broader legal authority.

FDA Drug Shortage Database (semaglutide shortage Feb 2022 – Feb 21 2025; tirzepatide shortage Dec 2022 – Dec 19 2024)

The FDA's official shortage list is documented and archived. For retroactive reimbursement claims, cite the specific dates semaglutide and tirzepatide were listed as in shortage. During these periods, compounding was unambiguously legal and often the only route to access the medication. If you started compounded therapy during the shortage and continued post-shortage, the continuity-of-care argument becomes much stronger.

STEP-1 trial (NEJM 2021)

This landmark trial demonstrated semaglutide 2.4 mg weekly produced 14.9% weight loss vs. 2.4% placebo over 68 weeks in adults with obesity. It is the foundational clinical evidence for Wegovy's FDA approval. Use STEP-1 to establish that semaglutide (compounded or branded) is not "investigational" or "cosmetic"—it is evidence-based obesity pharmacotherapy.

SELECT trial (NEJM 2023)

This cardiovascular outcomes trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in patients with established cardiovascular disease and obesity, independent of weight loss. SELECT expanded semaglutide's indication beyond weight management to cardiovascular risk reduction. If you have established ASCVD (prior MI, stroke, PAD), SELECT is a critical citation: your therapy is not cosmetic, it is cardioprotective.

SURMOUNT-1 trial (NEJM 2022)

Tirzepatide demonstrated dose-dependent weight loss up to 22.5% at the 15 mg dose over 72 weeks. This trial underpins Zepbound's approval. Like STEP-1 for semaglutide, SURMOUNT-1 establishes tirzepatide as evidence-based treatment for obesity.

AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (2013, updated 2022)

These joint society guidelines recommend pharmacotherapy as part of comprehensive obesity treatment for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Use this guideline to counter "not medically necessary" denials: your treatment aligns with national clinical practice standards.

ACA Section 2719(b) External Review Rights (45 CFR 147.136)

For non-grandfathered health plans, the Affordable Care Act guarantees external review by an independent reviewer when an insurer denies a claim as "not medically necessary" or "investigational." This is a procedural right, not a clinical argument, but it is enforcingly powerful: insurers know external reviewers often overturn denials, particularly when substantial clinical evidence exists.

ERISA Section 503 Appeal Rights (29 CFR 2560.503-1)

If your plan is employer-sponsored and self-funded, it is governed by ERISA. You have a right to a "full and fair review" of your denial, including access to all documents the plan relied on, a written explanation of the denial, and (for disability-related claims) external review under the ACA. Even weight-loss exclusions can be challenged if the therapy is prescribed for comorbid conditions (diabetes, cardiovascular disease, sleep apnea).

How to Argue Against "Not FDA-Approved" or "Investigational" Denials

When your insurer denies compounded GLP-1 coverage on the grounds that it is "not FDA-approved" or "investigational," you are facing a fundamental misunderstanding—or deliberate misrepresentation—of federal compounding law.

Step 1: Cite 21 USC §353a directly

In your appeal letter, quote the statute: "Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound drugs for individual patients based on a valid prescription from a licensed prescriber, without requiring FDA approval of the compounded product. Compounding is explicitly authorized when a commercially available drug cannot meet the patient's medical needs or when a drug is in shortage."

Step 2: Distinguish compounded semaglutide/tirzepatide from "investigational" drugs

Investigational drugs are unapproved molecules in clinical trials. Semaglutide and tirzepatide are FDA-approved active pharmaceutical ingredients (APIs). Compounded versions use the identical API in a patient-specific formulation. This is not experimentation—it is individualized medicine using a proven molecule. Reference STEP-1, SELECT, and SURMOUNT-1 to show decades of clinical evidence support the safety and efficacy of these molecules.

Step 3: Demonstrate why branded products could not meet your needs

Even if Wegovy or Zepbound are now available, you must show why compounded was or remains medically appropriate. Examples:

• You started compounded therapy during the shortage (Feb 2022 – Feb 2025 for semaglutide; Dec 2022 – Dec 2024 for tirzepatide), and abrupt discontinuation mid-titration is unsafe.
• Branded products were denied by your insurer due to formulary restrictions, prior authorization denials, or cost (manufacturer copay cards only work if you have coverage).
• You are on a dose not available in branded formulations (e.g., 1.7 mg semaglutide weekly is not a standard Wegovy pen dose).
• Regional or dose-specific stockouts persist at retail pharmacies despite official shortage end.

Step 4: If your compound includes B12 or other ingredients, invoke the "different drug" argument

If you are prescribed compounded semaglutide + B12 or tirzepatide + B12/niacinamide, your compound is arguably a distinct formulation from the branded product. Under 21 USC §353a, pharmacies may compound combinations when a prescriber determines the combination meets a clinical need the FDA-approved product cannot. For example, if you have documented B12 deficiency (common with GLP-1 therapy due to reduced intrinsic factor or dietary intake), the combination addresses two clinical problems simultaneously. Attach lab results showing low or low-normal B12, methylmalonic acid, or homocysteine levels, plus a prescriber letter explaining the rationale for combination therapy.

Step 5: Request external review under ACA Section 2719

If your plan is non-grandfathered and ACA-compliant (most commercial plans), state in your appeal: "I request external review of this denial under ACA Section 2719(b) and 45 CFR 147.136. The plan's determination that compounded semaglutide is 'investigational' contradicts federal compounding statutes and extensive clinical trial evidence. I request an independent clinical reviewer with expertise in obesity medicine evaluate this claim." External reviewers are often endocrinologists or bariatric specialists who understand GLP-1 therapy and are not beholden to the insurer's cost-containment incentives.

How to Argue Against Weight-Loss Medication Exclusions

Employer plan carve-outs for anti-obesity medications are common, particularly in self-funded ERISA plans. These exclusions can be difficult to overcome, but they are not absolute.

Step 1: Recharacterize the indication

If you have type 2 diabetes, prediabetes (A1c 5.7–6.4%), or established cardiovascular disease, you are not seeking "weight-loss medication"—you are seeking diabetes management or cardiovascular risk reduction. Semaglutide is FDA-approved for type 2 diabetes (as Ozempic) independent of its weight-loss indication. Cite your A1c, fasting glucose, or prior cardiovascular events (MI, stroke, stent, CABG, PAD) and request coverage under the diabetes or cardiology benefit, not the weight-loss exclusion.

Step 2: Use SELECT trial for cardiovascular indication

If you have established ASCVD and obesity, the SELECT trial is your cornerstone. Write: "I am not requesting this medication for cosmetic weight loss. I have documented coronary artery disease [attach cardiac cath report, stress test, prior MI documentation] and obesity (BMI [X]). The SELECT trial (NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in this exact patient population. My cardiologist has determined this therapy is medically necessary to reduce my risk of recurrent MI and cardiovascular death."

Step 3: Document weight-related comorbidities exhaustively

The more comorbidities you have, the stronger your case that this is not cosmetic. List:

• Hypertension (medication names, BP logs)
• Dyslipidemia (lipid panels, statin use)
• Obstructive sleep apnea (sleep study results, CPAP compliance data)
• Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD—ultrasound or FibroScan results)
• Polycystic ovary syndrome (PCOS—ultrasound, hormone panels)
• Osteoarthritis (imaging, joint injections, limitations in activities of daily living)
• Prediabetes (A1c 5.7–6.4%)

Attach the AHA/ACC/TOS 2013 (updated 2022) guidelines and highlight the recommendation for pharmacotherapy in patients with BMI ≥27 plus weight-related comorbidities. Your therapy aligns with national standards of care.

Step 4: Document prior weight-loss interventions and failures

Insurers often require "step therapy" even when not explicitly stated. Show that lifestyle modification alone was insufficient:

• Documented participation in a structured weight-loss program (WeightWatchers, MOVE!, registered dietitian counseling) for at least 6 months with weight logs.
• Prior trials of phentermine, orlistat, naltrexone-bupropion, or other weight-loss medications with documented side effects or inadequate response.
• Bariatric surgery evaluation (if applicable) with documentation of why surgery was declined, contraindicated, or resulted in insufficient weight loss or weight regain.

Step 5: Challenge the exclusion's legality under the Mental Health Parity and Addiction Equity Act (MHPAA) or state law

Some states (e.g., Delaware, Maryland, Massachusetts) have enacted laws requiring coverage of FDA-approved obesity medications when medically necessary. If you live in such a state, cite the statute in your appeal. Additionally, if your plan covers weight-loss medications for diabetes (e.g., Ozempic, Mounjaro) but excludes them for obesity, you may have a parity argument: obesity is a recognized chronic disease (AMA 2013 resolution), and differential treatment may violate parity principles or constitute discrimination under ERISA's fiduciary duty standards.

Step 6: Escalate to ERISA appeal and DOL complaint if necessary

If your first-level appeal is denied, you have a right to a full and fair review. Request all documents the plan relied on (policy language, medical director's rationale, clinical guidelines cited). If the plan's exclusion is buried in fine print, not clearly disclosed, or inconsistently applied, consider filing a complaint with the Department of Labor's Employee Benefits Security Administration (EBSA). Self-funded plans are subject to ERISA's fiduciary duty standards, and arbitrary or inconsistent denials can trigger DOL scrutiny.

How to Argue for Retroactive Reimbursement of Cash Purchases During Shortage

Thousands of patients paid $200-$500 per month out of pocket for compounded semaglutide or tirzepatide from mid-2022 through early 2025, accumulating $3,000-$10,000+ in expenses. Insurers reflexively deny reimbursement claims, but federal and state laws create potential pathways.

Step 1: Document the FDA shortage period precisely

Attach screenshots or citations from the FDA Drug Shortage Database showing semaglutide was listed from February 2022 through February 21, 2025, and tirzepatide from December 2022 through December 19, 2024. Argue: "During this period, branded Wegovy and Zepbound were unavailable at retail pharmacies nationwide. Compounded versions were the only route to access FDA-approved active pharmaceutical ingredients for evidence-based obesity treatment."

Step 2: Show you attempted to obtain coverage and were denied or delayed

If you submitted a prior authorization for Wegovy or Zepbound and were denied, attach the denial letter. If you were told the drug was not in stock and placed on indefinite backorder, attach pharmacy correspondence. If you were told your plan excluded weight-loss medications, attach the Summary Plan Description (SPD) excerpt and the denial. The key argument: "I sought coverage through my plan's normal channels. The plan's denial and the nationwide shortage left me no option but to pay cash for compounded therapy to avoid medically unsafe treatment gaps."

Step 3: Argue the plan's failure to cover branded drugs during shortage obligates reimbursement of the compounded alternative

If your plan theoretically covers Wegovy or Zepbound but the drugs were unavailable, you have a strong argument: "The plan's benefit documents promise coverage of FDA-approved GLP-1 agonists for obesity. During the shortage, the plan's contracted pharmacies could not fulfill this promise. I obtained the same active pharmaceutical ingredient from a licensed 503A pharmacy as permitted by federal law. The plan is obligated to reimburse the reasonable cost of obtaining the covered benefit through the only available route."

Step 4: Cite your state's prudent layperson standard or emergency coverage rules

Some states require insurers to cover out-of-network emergency care based on a "prudent layperson" standard—a reasonable person believing delay would jeopardize health. While compounded GLP-1 is not an emergency, abrupt discontinuation mid-titration can cause rebound weight gain, worsening of cardiovascular risk factors, and psychological distress. If your state has consumer protection laws requiring coverage of medically necessary care when in-network options are unavailable, cite them.

Step 5: Submit itemized receipts and a detailed treatment timeline

Your reimbursement claim must be meticulously documented:

• Receipts from the telehealth provider and compounding pharmacy (Henry Meds, Hims, Mochi, etc.) showing dates, doses, and amounts paid.
• A prescriber letter documenting the start date, dose titration schedule, clinical response (weight loss, HbA1c reduction, BP improvement), and medical necessity of uninterrupted therapy.
• Correspondence showing your attempts to obtain branded products or coverage.

Step 6: Request external review

If your reimbursement claim is denied, request external review under ACA Section 2719 (if applicable) or your state's external review process. Frame the issue as a coverage determination: "This is a dispute over whether the plan must cover medically necessary obesity pharmacotherapy when the plan's contracted pharmacies could not provide the FDA-approved branded product during a documented national shortage."

How to Argue for Continued Compounded Therapy Post-Shortage

After February 2025 (semaglutide) and December 2024 (tirzepatide), the legal footing for continued compounding became murkier, but it is not nonexistent.

Step 1: Invoke continuity of care

If you started compounded therapy during the shortage and are mid-titration (e.g., on 1.0 mg weekly semaglutide, target dose 2.4 mg), abrupt discontinuation or forced switch to branded risks rebound weight gain, loss of glycemic control, and worsening cardiovascular risk. Submit a prescriber letter stating: "Abrupt discontinuation is not medically appropriate. The patient requires continued titration to therapeutic dose. Switching to branded product at this juncture would introduce supply-chain uncertainty (dose-specific stockouts persist despite official shortage end) and financial barriers (the patient's plan denies coverage, and manufacturer copay cards are inaccessible without coverage)."

Step 2: Document ongoing branded supply instability

Even though the FDA removed these drugs from the shortage list, anecdotal reports of dose-specific and regional stockouts persist. If your local pharmacies cannot reliably fill branded prescriptions, document it: call three pharmacies, ask if they have your dose in stock, and summarize the responses in your appeal. Attach screenshots of GoodRx or pharmacy websites showing "out of stock" or "limited availability."

Step 3: Use the "different drug" argument for combination compounds

If you switched to compounded semaglutide + B12 or tirzepatide + niacinamide, argue this is not "essentially a copy" of Wegovy or Zepbound—it is a distinct formulation addressing multiple clinical needs. Attach labs showing B12 deficiency or low-normal B12 with elevated methylmalonic acid. Cite prescriber rationale for the combination (e.g., "Patient developed symptomatic B12 deficiency on branded semaglutide, evidenced by paresthesias and MCV 102. Combination compound allows single injection addressing both obesity and micronutrient deficiency, improving adherence and reducing injection burden").

Step 4: Argue financial and logistical barriers to branded products

If Wegovy or Zepbound are on your plan's formulary but require unaffordable copays ($500-$1,500/month), and manufacturer copay cards are only available to patients with commercial coverage (you may be on a plan that denies coverage, making you ineligible), you face an impossible bind. Argue: "The plan's policy effectively denies access to evidence-based obesity treatment. I cannot afford $1,200/month for branded Wegovy without copay assistance, which I cannot access because the plan denies coverage. Compounded semaglutide at $300/month from a licensed 503A pharmacy is the only financially feasible route to continue medically necessary therapy."

Step 5: Request a medical necessity determination and external review

If the plan denies continued compounded therapy, request a formal medical necessity review. Submit a comprehensive prescriber letter, your full treatment timeline, clinical response data (weight loss, A1c reduction, BP logs, lipid panels), and documentation of barriers to branded products. If denied, request external review: "I request an independent clinical reviewer determine whether continued compounded semaglutide is medically necessary given the patient's mid-titration status, documented clinical response, and insurmountable financial and supply-chain barriers to branded alternatives."

What We Do

We help patients and advocates build appeals that survive insurer scrutiny and external review. Our work involves dissecting your Summary Plan Description and Evidence of Coverage, identifying whether your plan is ERISA-governed or state-regulated, pulling the exact clinical trial data and federal statutes your case requires, and drafting multi-page appeal letters that match the tone and evidentiary standards of what wins at external review. We also guide you through retroactive reimbursement claims, including negotiating with telehealth providers and compounding pharmacies for detailed documentation. Compounded GLP-1 denials involve overlapping federal drug law, insurance contract interpretation, and clinical evidence synthesis—we handle all three layers.

Sources

1. 21 USC §353a (Federal Food, Drug, and Cosmetic Act Section 503A—Pharmacy Compounding)

2. 21 USC §353b (Section 503B—Outsourcing Facilities)

3. FDA Drug Shortage Database, semaglutide and tirzepatide shortage periods (fda.gov/drugs/drug-safety-and-availability/drug-shortages)

4. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP-1 trial). New England Journal of Medicine 2021;384:989-1002.

5. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT trial). New England Journal of Medicine 2023;389:2221-2232.

6. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1 trial). New England Journal of Medicine 2022;387:205-216.

7. AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (2013, updated 2022). Circulation and Journal of the American College of Cardiology.

8. 45 CFR 147.136 (ACA Section 2719 External Review)

9. 29 CFR 2560.503-1 (ERISA Section 503 Claims Procedure)

10. American Medical Association, "AMA Adopts New Policies on Second Day of Voting at Annual Meeting" (Resolution recognizing obesity as a disease, 2013)